guest ::
| Home > Publications database > The role of zongertinib, a highly selective tyrosine kinase inhibitor, in targeting HER2-mutant NSCLC: a bench-to-bedside review. > print |
| Home > Publications database > The role of zongertinib, a highly selective tyrosine kinase inhibitor, in targeting HER2-mutant NSCLC: a bench-to-bedside review. > print |
| 001 | 309658 | ||
| 005 | 20260205153003.0 | ||
| 024 | 7 | _ | |a 10.1080/14737140.2026.2623059 |2 doi |
| 024 | 7 | _ | |a pmid:41640088 |2 pmid |
| 024 | 7 | _ | |a 1473-7140 |2 ISSN |
| 024 | 7 | _ | |a 1744-8328 |2 ISSN |
| 037 | _ | _ | |a DKFZ-2026-00290 |
| 041 | _ | _ | |a English |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Heymach, John V |b 0 |
| 245 | _ | _ | |a The role of zongertinib, a highly selective tyrosine kinase inhibitor, in targeting HER2-mutant NSCLC: a bench-to-bedside review. |
| 260 | _ | _ | |a Abingdon, Oxon |c 2026 |b Taylor & Francis |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1770301793_2393090 |2 PUB:(DE-HGF) |x Review Article |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 500 | _ | _ | |a #NCTZFB9# / epub |
| 520 | _ | _ | |a HER2 is mutated in 2-4% of non-small cell lung cancers (NSCLC) and is associated with poor prognosis. Tyrosine kinase inhibitors (TKIs) targeting HER2 have historically been hampered by insufficient efficacy against exon 20 insertion mutations and lack of specificity, resulting in off-target adverse events. Zongertinib is an oral, irreversible HER2-selective TKI that spares wild-type EGFR, thereby minimizing associated toxicities. Zongertinib was recently approved in the United States (accelerated), China (conditional), and Japan for patients with previously treated advanced HER2-mutant NSCLC.This article outlines the discovery and clinical development of zongertinib that led to these approvals. We discuss the first-in-human Beamion LUNG-1 trial (NCT04886804), in which zongertinib demonstrated encouraging and durable activity, with a manageable safety profile, in patients with HER2-mutant advanced NSCLC. Finally, we summarize ongoing clinical trials of zongertinib, including its assessment as first-line treatment for advanced HER2-mutant NSCLC.Zongertinib is the first oral TKI approved for HER2-mutant NSCLC and will provide patients with a convenient, tolerable and effective treatment option in an area of significant unmet need. Next steps include its potential transition to a first-line setting, identification of additional indications, and development of novel combination regimens. |
| 536 | _ | _ | |a 899 - ohne Topic (POF4-899) |0 G:(DE-HGF)POF4-899 |c POF4-899 |f POF IV |x 0 |
| 588 | _ | _ | |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de |
| 650 | _ | 7 | |a Zongertinib |2 Other |
| 650 | _ | 7 | |a human epidermal growth factor receptor 2 |2 Other |
| 650 | _ | 7 | |a non-small cell lung cancer |2 Other |
| 650 | _ | 7 | |a targeted therapy |2 Other |
| 650 | _ | 7 | |a tyrosine kinase inhibitor |2 Other |
| 700 | 1 | _ | |a Popat, Sanjay |b 1 |
| 700 | 1 | _ | |a Smit, Egbert F |b 2 |
| 700 | 1 | _ | |a Christopoulos, Petros |0 P:(DE-He78)a22d618e20924210eb7b3af630a45441 |b 3 |u dkfz |
| 700 | 1 | _ | |a Planchard, David |b 4 |
| 700 | 1 | _ | |a Yoshida, Tatsuya |b 5 |
| 700 | 1 | _ | |a Zugazagoitia, Jon |b 6 |
| 700 | 1 | _ | |a Yu, Yan |b 7 |
| 700 | 1 | _ | |a Wilding, Birgit |b 8 |
| 773 | _ | _ | |a 10.1080/14737140.2026.2623059 |g p. 14737140.2026.2623059 |0 PERI:(DE-600)2090850-7 |p nn |t Expert review of anticancer therapy |v nn |y 2026 |x 1473-7140 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 3 |6 P:(DE-He78)a22d618e20924210eb7b3af630a45441 |
| 913 | 1 | _ | |a DE-HGF |b Programmungebundene Forschung |l ohne Programm |1 G:(DE-HGF)POF4-890 |0 G:(DE-HGF)POF4-899 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-800 |4 G:(DE-HGF)POF |v ohne Topic |x 0 |
| 914 | 1 | _ | |y 2026 |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b EXPERT REV ANTICANC : 2022 |d 2025-11-11 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2025-11-11 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2025-11-11 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2025-11-11 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1110 |2 StatID |b Current Contents - Clinical Medicine |d 2025-11-11 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0160 |2 StatID |b Essential Science Indicators |d 2025-11-11 |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0113 |2 StatID |b Science Citation Index Expanded |d 2025-11-11 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2025-11-11 |
| 915 | _ | _ | |a IF < 5 |0 StatID:(DE-HGF)9900 |2 StatID |d 2025-11-11 |
| 920 | 1 | _ | |0 I:(DE-He78)HD02-20160331 |k HD02 |l Koordinierungsstelle NCT Heidelberg |x 0 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a I:(DE-He78)HD02-20160331 |
| 980 | _ | _ | |a UNRESTRICTED |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|